Indication
Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients (see section 5.1). Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (ESA) after their haemoglobin level was stabilised with the previous ESA (see section 5.1).
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Mircera 100 µg / 0,3 ml, oplossing voor injectie (in voorgevulde spuit)NetherlandsAuthorised
- Mircera 120 µg/0,3 ml, oplossing voor injectie (in voorgevulde spuit)NetherlandsAuthorised
- Mircera 150 µg / 0,3 ml, oplossing voor injectie (in voorgevulde spuit)NetherlandsAuthorised
- Mircera 200 µg / 0,3 ml, oplossing voor injectie (in voorgevulde spuit)Netherlands